New drug cocktail takes aim at stubborn leukemia
NCT ID NCT06445907
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding an experimental drug called Q702 to two standard leukemia drugs (azacitidine and venetoclax) is safe for people with relapsed or refractory acute myeloid leukemia (AML). About 17 adults whose leukemia has not responded to or has returned after other treatments will take part. The main goal is to check for side effects and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Q702 (an experimental drug taken by mouth) combined with azacitidine (given by IV) and venetoclax (taken by mouth)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat acute myeloid leukemia.
What could go wrong
This is a very early (Phase 1) trial with only 17 participants, so it's mainly checking safety, not effectiveness. The combination may not work or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States